Citation tools
"The bulky N(6) substituent of cabergoline is responsible for agonism of this drug at serotonin 5-HT2A and 5-HT2B receptors and thus a determinant of valvular heart disease." Journal of Pharmacology and Experimental Therapeutics
(2011):
jpet.111.181255.
Web. 19 April. 2024.